Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune myasthenia gravis

G Lopate1, A Pestronk

  • 1Washington University, St. Louis.

Hospital Practice (Office Ed.)
|January 15, 1993
PubMed
Summary
This summary is machine-generated.

This disease involves postsynaptic dysfunction caused by anti-acetylcholine receptor antibodies, leading to reduced acetylcholine receptors and impaired neuromuscular transmission. Management includes antiacetylcholinesterase drugs and newer options like prednisone, azathioprine, and cyclosporine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Journal of neurology, neurosurgery, and psychiatry·2015
Same author

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy.

Neurology·2012
Same author

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Neurology·2011
Same author

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Neurology·2011
Same author

Dominant spinal muscular atrophy with lower extremity predominance: linkage to 14q32.

Neurology·2010
Same author

[A transferable "Myasthenogenic" factor in the serum of patients with myasthenia gravis.].

Journal of neurology·2010
Same journal

Oral contraceptives: an update.

Hospital practice (Office ed.)·1995
Same journal

Progress in the immunogenetics of rheumatoid arthritis.

Hospital practice (Office ed.)·1995
Same journal

An asymptomatic lung nodule in an elderly woman with joint pain.

Hospital practice (Office ed.)·1995
Same journal

Defusing status epilepticus.

Hospital practice (Office ed.)·1995
Same journal

Persistent fever and flank discomfort in a young woman.

Hospital practice (Office ed.)·1995
Same journal

New thoughts on attention-deficit/hyperactivity disorder.

Hospital practice (Office ed.)·1995
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • The primary defect in this condition is postsynaptic dysfunction.
  • This dysfunction stems from autoantibodies targeting acetylcholine receptors.
  • Consequences include a simplified postsynaptic membrane and diminished neuromuscular transmission.

Purpose of the Study:

  • To elucidate the pathophysiological mechanisms underlying postsynaptic dysfunction.
  • To review current and emerging therapeutic strategies for managing this autoimmune disorder.

Main Methods:

  • Analysis of the molecular and cellular changes at the neuromuscular junction.
  • Review of pharmacological interventions and their efficacy.

Main Results:

Related Experiment Videos

  • Reduced number and accessibility of acetylcholine receptors.
  • Impaired neuromuscular signal transmission.
  • Established role of antiacetylcholinesterase drugs.
  • Emerging immunomodulatory therapies including prednisone, azathioprine, and cyclosporine.

Conclusions:

  • Postsynaptic dysfunction is central to the disease's pathology.
  • Pharmacological interventions targeting acetylcholine receptors and immune modulation are key management strategies.